CytoDyn Inc‘s (OTCMKTS:CYDY) new drug, Leronlimab, proven effective in the fight against AIDS and certain cancers, has now emerged as the leading contender among candidate drugs to treat COVID-19 across all levels of severity.
The company’s stock has tripled since it received Emergency Investigative New Drug (EIND) certification from the FDA, but the story is still in its infancy. Investors who get in now could experience a life-changing wealth transformation.
I spoke to CEO Dr. Nader Pourhassan last week as soon as I heard about this amazing drug, which so far has eluded the attention of mainstream financial media. Not surprisingly, they tend to lavish all of their attention on multi-billion dollar globalized conglomerates like Johnson and Johnson, Merck, Pfizer and Gilead.
That’s why Cytodyn is such a great find.
Dr. Pourhassan was excited during the interview, to say the least.
It is obvious to me that he and his team of scientists are on to what could be the cure for COVID-19 illness.
According to Samantha Mottet, a 55-year old from Seal Beach, California, this new drug (leronlimab) is the reason she survived the later stages of COVID-19 after being left to die on a ventilator.
She and her husband were offered a spot on a clinical trial being conducted by Dr. Otto Yang, a professor of medicine at UCLA’s David Geffen School of Medicine that is testing CytoDyn’s leronlimab.
“My husband and I had been vomitting and having diarrhea and I didn’t even realize,” Mottet reported. “That whole week was just a blur…”.
Dr. Yang says that lenonlimab is an artificial antibody developed by Cytodyn that works best against the later phases of the COVID-19 illness – which are typically the most dangerous and result in the highest incident of death.
The body’s immune system overreacts in response to the virus, causeing inflammation of the lungs that blocks breathing in patients.
This overreaction causes the replication of the COVID-19 virus at the rate of billions per day, which induces Acute Respiratory Distress Syndrome (ARDS), which is actually the cause of death in most cases of COVID-19.
Leronlimab actually halts the replication of the cells, resulting in an immediate reduction in inflamation that essentially induces immediate and permanent relief from the ARDS.
Within 24 hours, Samantha started needing less oxygen, and within 48 hours, no longer needed a ventilator at all.
Last week, the company’s drug was administered to 15 patients at a leading medical center in New York, where the highest number of deaths from COVID-19 have been logged in the United States.
Over the next two weeks, another 340 severely ill patients will get access to the drug through the Emergency Investigational New Drug (EIND) protocol administered by the FDA, and individually approved on a case-by-case basis when all else has failed.
So we know this drug is working.
But how long until a little company like Cytodyn could possibly produce the tens of millions of doses that may be required by the global pandemic?
That’s why this is such an urgent opportunity.
The FDA has granted the company fast track status for a Phase II trial now for mild to moderate cases, plus a Phase III trial for severe cases.
According to Dr. Pourhassan, Cytodyn has already engaged the services of Samsung Biologics to produce 600,000 to 700,000 doses by summer. But Samsung Biologics, one of the world’s largest Contract Drug Manufacturers in the world, is ready and equipped to make millions of doses.
“If I called them today, and said I need 5 million doses, they would be able to have them ready for us this year,” he says.
Five million doses in a year is exactly the rate of production that will be required if this drug continues to cure people of COVID-19.
Just imagine, with this drug in place, Donald Trump would be able to achieve his dream of getting America open and back to work by May 1st.
And with 5 million doses on the horizon in the near-term, the whole world could breathe a sigh of relief, as life begins to return to normal.
Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.
Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.
Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.